Knowledge Base:  
You are here: Knowledge Base >
Beta Glucan Resource Center
Last Updated: 12/23/2014
Beta Glucan Resource Center

Here you will find links to articles, studies, and audio and video presentations to help you better understand Beta glucan and how it works to support your immune system

Interviews range from approximately 15-30 minutes each)

Beta Glucan and the Immune System - VIDEO

Mode of Action - VIDEO

A.J. Lanigan Interview - Beta Glucan - AUDIO
Health, Wealth and Happiness Radio Talk Show hosted by: Gary Pozsik

Sharon T. Lewis, R.N. Interview - Beta Glucan - AUDIO
Health, Wealth and Happiness Radio Talk Show hosted by: Gary Pozsik


History of Beta Glucan

Why Transfer Point is the Best Beta Glucan

Beta Glucan JANA Studies, 2007

Beta Glucan - Medlines

Beta Glucan and Nuclear Radiation

Quotes about Beta Glucan

Transfer Point Beta Glucan (Glucan 300®) versus Our Health Co-op
Comparison chart

Transfer Point Beta Glucan (Glucan 300®) versus Wellmune WGP
Comparison Chart

Biological Activity of Transfer Point’s Glucan 300®


Note - The Gucan #300 named in the following research papers refers to the patent name for Transfer Point Beta 1, 3D Glucan.

2011 -
Beta Glucan - Immunostimulant, Adjuvant, Potential Drug
World Journal of Clinical Oncology, February 2011
Download entire article in .pdf format

2010 - Beta 1,3-Glucan: Silver Bullet or Hot Air?
Open Glycoscience, 2010
Download entire article in .pdf format

2010 - Beta Glucan and Humic Acid: Synergistic Effects on the Immune System
Journal of Medicinal Food, 13 (4) 2010
Download entire article in .pdf format

2009 - Beta Glucan -Indomethacin Combination Produces No Lethal Effects
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.
Download entire article in .pdf format

2008 - A Comparison of Injected and Orally Administered B-glucans
JANA Vol 11, No. 1, 2008

October 2007 - Physiological Effects Of Different Types of Beta Glucan
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.

March 2007 - An Evaluation of the Immunological Activities of Commercially Available β1, 3-Glucans
JANA Vol.10, No. 1, 2007

September 2005 -Beta-Glucan Enhances Complement-Mediated Hematopoietic Recovery after Bone Marrow Injury
Blood First Edition Paper

June 2005 -C5a-Mediated Leukotriene B4-Amplified Neutrophil Chemotaxis is Essential in Tumor Immunotherapy
Facilitated by Anti-Tumor Monoclonal Antibody and ß-Glucan
The Journal of Immunology 2005 174:7050-7056

September 2004 - ß-Glucan Affects Leukocyte Navigation in a Complex Chemotactic Gradient
Surgery 2004: 136:384-89

July 15, 2004 - Mechanism by Which Orally Administered ß-1,3-Glucans Enhance the Tumorcidial Activity of Anti-Tumor Monoclonal Antibodies in Murine Tumor Models
The Journal of Immunology 2004: 173: 797-806

December 15, 2003 - ß-Glucan Functions as an Adjuvant for Monoclonal Antibody Immunotherapy by Recruiting Tumoricidal Granulocytes as Killer Cells
Cancer Research 63, 9023-9031, Dec. 15, 2003
A Journal of the American Association for Cancer Research
(See below for important information)
Download the entire article in .pdf format

Promising initial study results demonstrate that a soluble beta glucan compound significantly increased the effectiveness of monoclonal antibodies specific for the treatment of breast, liver and lung cancer, according to a recent article published in Cancer Research, a journal of the American Association for Cancer Research.
In a series of preclinical studies, a therapeutic combination of a patented, soluble yeast beta glucan called NSG and monoclonal antibodies significantly enhanced both tumor regression and long-term survival as compared with monoclonal antibody therapy alone. In the breast cancer model, 40 percent of the mice receiving the combined therapy survived long-term and tumor-free, compared with no survivors among mice treated with the monoclonal antibody or NSG alone. Similarly, in a liver cancer model the combined therapy extended survival and increased long-term survivorship by 25 percent.
“The data suggests that the therapeutic efficacy of certain complement-activating monoclonal antibodies, like Herceptin, Rituxan and Erbitux, could be significantly enhanced if they were combined with NSG,” said Gordon D. Ross, Ph.D., Director of the Tumor Immunobiology Program at the James Graham Brown Cancer Center located at the University of Louisville and the senior author of the paper. “Given the limited tumor-killing mechanisms available to monoclonal antibodies, soluble beta glucan engages another arm of the immune system to fight cancer. NSG is a potentially important adjuvant to monoclonal antibodies for enhancing long-term cancer survival by providing this additive effect to these immunotherapies.”
NSG effectively recruits neutrophils, which are innate immune cells, to engage in tumoricidal activities. Normally, these white blood cells do not engage in the fight against cancer cells since they are viewed as “self,” only respond to “nonself” cells. Dr. Ross discovered that NSG, a polysaccharide derived from a proprietary strain of yeast, binds to a specific receptor site on these innate immune cells, allowing them to “see” the cancer as “nonself” and trigger killing.
“This is notable research published in a very well respected medical journal devoted to cancer research. Other work performed by Dr. Ross and his colleagues have demonstrated that orally dosed Beta 1,3-D glucan is taken up by macrophages and neutrophils via the Peyer’s Patches in the gut. In a period of 3-12 days, these phagocytes digest the insoluble particles and convert them into a soluble form of beta glucan. We would encourage everyone to take this article and share it with physicians and particularly oncologists working with different forms of immunotherapy”.
1 – Cancer Research 63, 9023-9031 December 2003

March 24, 2003 - Anthrax-Protective Effects of Yeast Beta 1,3 Glucans
Medscape General Medicine
May 1, 2002 - Pilot Study: Orally-Administered Yeast ß1,3-glucan Prophylactically Protects Against Anthrax Infection and Cancer in Mice
The Journal of the American Nutraceutical Association Vol. 5, No. 2, Spring 2002

Was this article helpful?